Synchrogenix, a Certara company

synchrogenix.com

REGULATORY and MEDICAL WRITING By merging our cross-functional expertise with our writing experience, we deliver documents that not only support clients’ strategic messaging, but also enhance their marketability. We provide many of the benefits of in-house writers including the experience and perspective of industry insiders without increased overhead or struggles with fluctuating workloads.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

news image

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More

NEURAXPHARM AND PANAXIA GLOBAL HAVE ENTERED A COMPREHENSIVE AGREEMENT TO START A BUSINESS COLLABORATION

Panaxia Global, Neuraxpharm | July 22, 2020

news image

Neuraxpharm, a leading European pharmaceutical company specialized in CNS, and Panaxia Global, the controlling owner of Panaxia Labs Israel (Panaxia Israel) (TASE: PNAX), Israel's largest medical cannabis manufacturer, announced today they have entered a definite agreement to start a business collaboration for marketing Panaxia's medical cannabis products in Germany, Europe's largest and fastest-growing market for cannabis in Europe. The agreement, which anchors a previous MOU entere...

Read More

Pharmacy Market

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

news image

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More

Business Insights

INNOVENT AND GENFLEET ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR GFH925 (KRAS G12C INHIBITOR)

Innovent Biologics | September 02, 2021

news image

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and GenFleet Therapeutics (Shanghai) Inc., a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, today jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet&...

Read More
news image

Business Insights

PACK4U ACQUIRES LEADING PHARMACY TECHNOLOGY COMPANY CATALYST HEALTHCARE

Pack4U | January 07, 2022

Pack4U, a connected health services company, acquires long-time technology partner Catalyst Healthcare whose patented AdhereNet® platform links pharmacists, patients, and care teams to effectively manage drug complexity and improve medication adherence. "We are dedicated to improving patient outcomes at scale. Bringing this domain knowledge in-house is vital for Pack4U. Catalyst's CEO Shane Bishop is a pharmacy thought leader and we are excited a...

Read More
news image

NEURAXPHARM AND PANAXIA GLOBAL HAVE ENTERED A COMPREHENSIVE AGREEMENT TO START A BUSINESS COLLABORATION

Panaxia Global, Neuraxpharm | July 22, 2020

Neuraxpharm, a leading European pharmaceutical company specialized in CNS, and Panaxia Global, the controlling owner of Panaxia Labs Israel (Panaxia Israel) (TASE: PNAX), Israel's largest medical cannabis manufacturer, announced today they have entered a definite agreement to start a business collaboration for marketing Panaxia's medical cannabis products in Germany, Europe's largest and fastest-growing market for cannabis in Europe. The agreement, which anchors a previous MOU entere...

Read More
news image

Pharmacy Market

ARROWHEAD PHARMACEUTICALS INITIATES PHASE 1/2 STUDY OF ARO-C3 FOR TREATMENT OF COMPLEMENT MEDIATED DISEASES

Arrowhead Pharmaceuticals Inc. | February 19, 2022

Arrowhead Pharmaceuticals Inc. announced that it has dosed the first subjects in AROC3-1001, a Phase 1/2 clinical study of ARO-C3, the company’s investigational RNA interference (RNAi) therapeutic designed to reduce production of complement component 3 (C3) as a potential therapy for various complement mediated diseases. “We believe a C3 targeted drug has the potential to address multiple complement mediated and complement associated diseases, whe...

Read More
news image

Business Insights

INNOVENT AND GENFLEET ANNOUNCE EXCLUSIVE GLOBAL LICENSE AGREEMENT FOR GFH925 (KRAS G12C INHIBITOR)

Innovent Biologics | September 02, 2021

Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and GenFleet Therapeutics (Shanghai) Inc., a clinical-stage biotechnology company developing cutting-edge therapies in oncology and immunology, today jointly announced that they have entered into an exclusive license agreement for the development and commercialization of GenFleet&...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us